Home/Biosimilar Atlas/Companies/Celltrion

Celltrion

Biosimilar developer, South Korea. 10 development products across 10 molecules: adalimumab, aflibercept, bevacizumab, denosumab, infliximab, omalizumab, rituximab, tocilizumab, trastuzumab, ustekinumab.

First approval in the Atlas: Sep 2013, Remsima, infliximab (EMA)
FDAproducts approved10
EMAproducts approved10
MHRAproducts approved10
PMDAproducts approved8
HCproducts approved10
CDSCOproducts approved1
EDEproducts registered3
Connections
10molecules10products7 of 7markets0candidates in trials8companies on the same molecules

About Celltrion

Celltrion made the first antibody biosimilar approved in the West, its infliximab, in Europe in 2013, and has since built the largest antibody biosimilar portfolio of any company: ten molecules, all approved in the United States, Europe and Canada, eight in Japan. Its Japanese products are sold by Nippon Kayaku and its Gulf registrations come through Hikma, its manufacturing partner in Jordan. In 2025 and 2026 it added denosumab, tocilizumab, omalizumab and aflibercept, and its tocilizumab is the only one interchangeable in both forms in the United States. Its infliximab is also the only one with an under-the-skin version.

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
AdalimumabYuflyma CT-P17May 2023Feb 2021MHRASep 2023Dec 2021··5/7
AfliberceptEydenzelt CT-P42Oct 2025Feb 2025MHRAMar 2026Nov 2025··5/7
BevacizumabVegzelma CT-P16Sep 2022Aug 2022MHRASep 2022Jan 2023··5/7
DenosumabStoboclo / Osenvelt CT-P41Feb 2025Feb 2025MHRA·Sep 2025··4/7
InfliximabRemsima / Inflectra CT-P13Apr 2016Sep 2013MHRAJul 2014Jan 2014Sep 2021Jun 20177/7
OmalizumabOmlyclo CT-P39Mar 2025May 2024MHRAMar 2026Dec 2024··5/7
RituximabTruxima / Blitzima CT-P10Nov 2018Feb 2017MHRA·Apr 2019·Apr 20205/7
TocilizumabAvtozma CT-P47Jan 2025Feb 2025MHRASep 2025Oct 2025··5/7
TrastuzumabHerzuma CT-P6Dec 2018Feb 2018MHRAMar 2018Sep 2019·Apr 20206/7
UstekinumabSteqeyma CT-P43Dec 2024Aug 2024MHRAMar 2025Jul 2024··5/7

Month shown is the first approval or registration of that product in that market.

In development

ClinicalTrials.gov lists two comparative trials sponsored by Celltrion for two molecules: bevacizumab, rituximab. All of these candidates already have at least one approval in the seven markets.

MoleculeCandidateDeveloper or sponsorReference productPhaseDesignRegistry statusStartedPrimary completionIn the AtlasRegistry record
BevacizumabCT-P16CelltrionAvastinPhase 1Comparative PKCompletedAug 2017Dec 2017VegzelmaNCT03247673
RituximabCT-P10CelltrionMabTheraPhase 1Comparative PKCompletedFeb 2012Aug 2013Truxima / BlitzimaNCT01534884

Registry data from ClinicalTrials.gov, entered by the sponsors and not verified by any regulator. Status and dates are as posted; sponsors often update them late. Trials registered only on other registries, such as India's CTRI or China's ChiCTR, are not included. Checked 12 Sep 2026.

Companies on the same molecules

Developers whose portfolios overlap most with Celltrion, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

Reliance Life SciencesEight shared molecules: adalimumab, bevacizumab, denosumab, infliximab, omalizumab, rituximab, trastuzumab, ustekinumab14 molecules in its portfolioAmgenSeven shared molecules: adalimumab, aflibercept, bevacizumab, infliximab, rituximab, trastuzumab, ustekinumab8 molecules in its portfolioSamsung BioepisSeven shared molecules: adalimumab, aflibercept, bevacizumab, denosumab, infliximab, trastuzumab, ustekinumab10 molecules in its portfolioBiocon BiologicsFive shared molecules: aflibercept, bevacizumab, denosumab, trastuzumab, ustekinumab9 molecules in its portfolioPfizerFive shared molecules: adalimumab, bevacizumab, infliximab, rituximab, trastuzumab7 molecules in its portfolioZydus LifesciencesFive shared molecules: adalimumab, aflibercept, bevacizumab, rituximab, trastuzumab11 molecules in its portfolioAlvotechFour shared molecules: adalimumab, aflibercept, denosumab, ustekinumab5 molecules in its portfolioHeteroFour shared molecules: adalimumab, bevacizumab, denosumab, rituximab5 molecules in its portfolio

Chronology

Compare Celltrion with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.